Levosimendan not checked

Orion Corporation, Orion Pharma · ODM-109

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
6 active
12 in total · 8 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion”In the company’s words, NCT03541603 on ClinicalTrials.gov
Tested for
Amyotrophic Lateral Sclerosis (2 trials), Heart Failure With Normal Ejection Fraction (2 trials), Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction
Main trialPhase 3
“This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a 2:1 ratio to receive either levosimendan (1 -2 mg daily) or placebo for 48 weeks. The primary endpoint is slow vital capacity (SVC) at 12 weeks, with the impact on patient function assessed through 48 weeks, adjusted for patient outcome, using ALSFRS-R (combined assessment of…”In the company’s words, NCT03505021 on ClinicalTrials.gov
Other names
ODM-109

Other drugs for Amyotrophic Lateral Sclerosis

All 48 drugs for Amyotrophic Lateral Sclerosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Completed 23 Jul 2020 Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
Phase 3Terminated 18 Nov 2020 Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
Phase 2Completed 7 Apr 2020 Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2Completed 25 Apr 2023 Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Phase 2Ended not given Effects of Levosimendan in patients being weaned from venoarterial extracorporal membrane oxygenation. A randomized controlled investigator driven phase II trial
Phase 3Authorised not given Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock
Phase 2Authorised not given LEVOSAH - Pilot study comparing the effectiveness of adding treatment with Levosimendan to usual care for the management of the acute phase of aneurysmal subarachnoid hemorrhages
Phase 3Ended not given A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial)
Phase 3Authorised not given LEONARD. Levosimendan vs. Placebo Before Isolated Tricuspid Valve Surgery
Phase 2Authorised not given Levosimendan in Cardiac Arrest: A Randomized Double-blinded Clinical Phase II Trial (LeICA)
Phase 4Authorised not given Shorter weaning from invasive ventilation with levosimendan: a randomized, double-blind, multicenter study in critically ill patients.
Phase 3/4Authorised not given LEVOMEMS: Comparison of the Hemodynamic Profile of Dobutamine and Levosimendan in the Current Therapeutic Context
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Levosimendan

Following is part of Solo: you see every change to Levosimendan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in